HC Wainwright Has Negative Estimate for RGLS FY2024 Earnings

Regulus Therapeutics Inc. (NASDAQ:RGLS) – Investment analysts at HC Wainwright cut their FY2024 earnings per share estimates for Regulus Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.86) per share for the year, down from their previous estimate of ($0.80). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Regulus Therapeutics’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Regulus Therapeutics’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

A number of other brokerages also recently issued reports on RGLS. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Regulus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Regulus Therapeutics Trading Down 3.8 %

Regulus Therapeutics stock opened at $1.50 on Thursday. The stock has a 50-day moving average price of $1.55 and a two-hundred day moving average price of $1.81. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The company has a market capitalization of $98.25 million, a PE ratio of -1.40 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RGLS. Creative Planning bought a new stake in shares of Regulus Therapeutics in the third quarter valued at $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics in the 3rd quarter valued at about $33,000. Rhumbline Advisers purchased a new stake in Regulus Therapeutics during the second quarter valued at about $136,000. Tyche Wealth Partners LLC boosted its position in Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 95,694 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Regulus Therapeutics in the third quarter worth about $204,000. Institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.